![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1394007
Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀå ¿¹Ãø(-2027³â) : Áö¿ªº° ºÐ¼® - Á¦Ç°º°, ½Ã¼úº°, ÃÖÁ¾»ç¿ëÀÚº°South & Central America Structural Heart Market Forecast to 2028 - Regional Analysis - by Product, Procedure, and End User |
Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀåÀº 2023³â 7¾ï7068¸¸ ´Þ·¯¿¡¼ 2028³â¿¡´Â 11¾ï 4,835¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2028³â±îÁö ¿¬Æò±Õ 6.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
½ÉÇ÷°ü Áúȯ ȯÀÚ ¼ö Áõ°¡¿Í ±³À° ÇÁ·Î±×·¥ Áõ°¡·Î Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå ¼ºÀå ÃËÁø
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, Áß³²¹Ì¿¡¼´Â ½ÉÇ÷°ü ÁúȯÀÌ »ç¸Á ¿øÀÎ 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½ÉÇ÷°ü ÁúȯÀ» ÅëÁ¦Çϱâ À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ½ÉÀåÆÇ¸·ÁõÀº ½ÉºÎÀüÀÇ °¡Àå ÈçÇÑ ¿øÀÎ Áß Çϳª°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ëµ¿¸ÆÆÇ¸·°ú ½Â¸ðÆÇ¸·ÀÇ ÅðÇ༺ Áúȯ, »ï÷ÆÇ¸·ÀÇ ±â´ÉºÎÀü ÁúȯÀº ÁßÁõÀ¸·Î ÁøÇàµÉ¼ö·Ï ÀÓ»ó °æ°ú°¡ ¾Çȵ˴ϴÙ. ±¸Á¶Àû ½ÉÁúȯ¿¡ ´ëÇÑ Àúħ½ÀÀû, ¿Ü°úÀû, Ä«Å×ÅÍ »ðÀÔ¼úÀÌ ÃÖ±Ù ±Þ°ÝÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±¸Á¶Àû ½ÉÁúȯÀº ½ÉÀåÆÇ¸· ¼ö¼ú°ú °æÇÇÀû Ä«Å×ÅÍ Ä¡·á·Î ±¸¼ºµÈ ¹ßÀüÇÏ´Â ºÐ¾ßÀ̱⠶§¹®¿¡ ½ÉÀå¿Ü°ú Àü¹®ÀÇ¿Í ³»°ú Àǻ縦 À§ÇÑ ´Ù¾çÇÑ ±³À° ÇÁ·Î±×·¥ÀÌ ¸¶·ÃµÇ¾î ÀÖ½À´Ï´Ù. Áö³ 10³â°£ ±¸Á¶Àû ½ÉÁúȯÀÇ ¹ß»ý·üÀÌ ±Þ°ÝÈ÷ Áõ°¡ÇÔ¿¡ µû¶ó ÀûÀýÇÑ ¿ª·®À» °®Ãá ÀÎÀ縦 È®º¸Çϱâ À§ÇÑ °ø½ÄÀûÀÎ ±³À° ÇÁ·Î±×·¥ °³¹ßÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ±³À° ±¸¼º, ±â°£, ¹üÀ§´Â ÇÁ·Î±×·¥¸¶´Ù Å©°Ô ´Ù¸¨´Ï´Ù. ´ëºÎºÐÀÇ ÇÁ·Î±×·¥¿¡¼ °æ Ä«Å×ÅÍ ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)À» È®½ÇÈ÷ ¹è¿ì´Â µ¿½Ã¿¡ ½É¹æ Áß°Ý °á¼Õ ¹× ½É½Ç Áß°Ý °á¼Õ Æó¼â¼ú, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â¼ú, ¼±Ãµ¼º ½ÉÀ庴 ÁßÀç¼ú¿¡ ´ëÇÑ ´Ù¾çÇÑ °æÇèÀ» ½×À» ¼ö ÀÖÁö¸¸, TAVR, MitraClip ½Â¸ðÆÇ¸· º¹±¸ ½Ã½ºÅÛ(Abbott Vascular), ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â¼ú(LAAO)ÀÇ ÃâÇöÀ¸·Î º¹ÀâÇÑ ½ÉÇ÷°ü°è ÁúȯÀ» °¡Áø ȯÀÚÀÇ Ä¡·á¸¦ À§ÇÑ ±¸Á¶Àû ½ÉÀå Áúȯ ¼ö¼úÀÇ ¾çÀÌ Å©°Ô Áõ°¡ÇÏ¿´½À´Ï´Ù. ¸¹Àº Á¶Á÷¿¡¼ ȯÀÚ À¯ÀÔ¿¡ ´ëÀÀÇϱâ À§ÇØ ±¸Á¶Àû ½ÉÀå ÇÁ·Î±×·¥À» À§ÇÑ Ã¼°èÀûÀÎ ÇüÅÂÀÇ ¼ºñ½º ¹× ½Ã¼ú Á¦°øÀ» °³¹ßÇßÀ¸¸ç, SHD ÈÆ·ÃÀº Èï¹Ì·Ó°í µµÀüÀûÀ̸ç Àü¹ÝÀûÀ¸·Î º¸¶÷ ÀÖ´Â ÀÏÀÔ´Ï´Ù. ÀÌ ºÐ¾ß°¡ ¹ßÀüÇÔ¿¡ µû¶ó SHD ±³À°ÀÇ Ç¥ÁØÈ´Â ȯÀÚ Ä¡·áÀÇ ÃÖ°í ǰÁúÀ» º¸ÀåÇϱâ À§ÇØ ¸Å¿ì Áß¿äÇØÁý´Ï´Ù. ±³À°¿¡¼ ½Ç¹«·ÎÀÇ ¼º°øÀûÀÎ ÀüȯÀ» À§ÇØ ¸¹Àº °í·Á »çÇ×À» Ž»ö ÇÒ ¼öÀÖ´Â ÁöµµÀÚ¸¦ ã´Â °ÍÀÌ ÃÖ°íÀÇ ÀÚ»êÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀå °³¿ä
³²¹Ì ¹× Áß¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ÁúȯÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ ³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ºê¶óÁúÀº ¿¹Ãø ±â°£ µ¿¾È ÀÌ Áö¿ª¿¡¼ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á °ü±¤ ºÎ¹®ÀÇ ¹ø¿µ°ú ÃֽŠÀÇ·á Á¦Ç°¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡´Â Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÇ÷°ü Áúȯ°ú °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡´Â ÀÌ Áö¿ªÀÇ ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå ¼öÀÍ ¹× 2028³â±îÁö ¿¹Ãø(±Ý¾×)
Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå ¼¼ºÐÈ
Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀåÀº Á¦Ç°, ½Ã¼ú, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.
Á¦Ç°º°·Î Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀåÀº ¿ÀŬ·ç´õ, ȯÇü ¸µ, ½ÉÀå ÆÇ¸· dz¼± ¹× ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå¿¡¼ ¿ÀŬ·ç´õ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼ú±âº°·Î Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀåÀº ½ÉÀåÆÇ¸· ÇùÂøÁõ, ½ÉÀåÆÇ¸· ¿ª·ùÁõ, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼âºÎÀüÁõÀ¸·Î ±¸ºÐµÇ¸ç, 2022³â Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀå¿¡¼ ½ÉÀåÆÇ¸· ÇùÂøÁõ ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¹× ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â Áß³²¹Ì ±¸Á¶Àû ½ÉÀå Áúȯ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¹°¡º°·Î´Â Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì·Î ±¸ºÐµÇ¸ç, 2022³â Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀåÀº ºê¶óÁúÀÌ µ¶ÁÖÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd´Â Áß³²¹ÌÀÇ ±¸Á¶Àû ½ÉÁúȯ ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.
The South & Central America structural heart market is expected to grow from US$ 770.68 million in 2023 to US$ 1,148.35 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2023 to 2028.
Rising Number of Cardiovascular Disease Cases and Training Programs Fuel South & Central America Structural Heart Market
According to the World Health Organization (WHO), cardiovascular diseases are the second leading cause of death South & Central America. Therefore, various initiatives are being taken to control cardiovascular diseases. Heart valve disease is expected to be one of the most common causes of heart failure. Degenerative diseases of aortic and mitral valves, and diseases of dysfunctional tricuspid valves lead to a worse clinical course in severe cases. Minimally invasive, surgical, and catheter-based interventions for structural heart disease have increased dramatically recently. The structural heart is an evolving field consisting of heart valve surgeries and transcatheter procedures; therefore, various training programs are being arranged for cardiac surgeons and physicians. Over the past decade, the burgeoning incidence of structural heart disease has necessitated the development of formal training programs to ensure the appropriate competency of workforces. The structure, length, and scope of training vary greatly between programs. Most programs provide solid exposure on transcatheter aortic valve replacement (TAVR) procedures, simultaneously providing a lesser and variable experience of atrial septal or ventricular septal defect closure, left atrial appendage closure, and congenital heart defect interventions. With the advent of TAVR, the MitraClip mitral valve repair system (Abbott Vascular), and left atrial appendage occlusion (LAAO) procedures, there has been a significant increase in the volume of structural cardiac procedures performed for treating patients with complex cardiovascular conditions. Many organizations have developed services and procedural offerings in an organized format for the structural cardiac program to accommodate the influx of patients. Training in SHD is exciting, challenging, and rewarding overall. As the field evolves, standardization of SHD training becomes extremely important to ensure the best quality of patient care. Finding a mentor to help navigate the numerous considerations outlined can be the best asset to successfully transitioning from training to practice.
South & Central America Structural Heart Market Overview
The South and Central America structural heart is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to register the largest market share in this region during the forecast period. The flourishing medical tourism sector and growing government initiatives to create awareness about modern healthcare products are the factors contributing to the structural heart market growth in South & Central America. Additionally, the rising prevalence of cardiovascular diseases and hypertension is propelling the structural heart market growth in the region.
South & Central America Structural Heart Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Structural Heart Market Segmentation
The South & Central America structural heart market is segmented into product, procedure, end user, and country.
Based on product, the South & Central America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the South & Central America structural heart market in 2022.
Based on procedure, the South & Central America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the South & Central America structural heart market in 2022.
Based on end user, the South & Central America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share of the South & Central America structural heart market in 2022.
Based on country, the South & Central America structural heart market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America structural heart market in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, and Braile Biomedica Industry, Commerce and Representations Ltd are some of the leading companies operating in the South & Central America structural heart market.